The legal complaint alleges that the company misled shareholders by failing to disclose critical operational practices. Specifically, the suit claims Hims & Hers shared private consumer health data with third-party advertising platforms and charged customers for prescriptions immediately after intake forms were submitted, contradicting public claims that users would consult with medical providers to determine appropriate treatments. These omissions allegedly drew regulatory scrutiny and exposed the company to potential financial penalties, undermining the validity of positive statements made about the firm’s business prospects during the class period.

Investors seeking to participate in the litigation must file a motion with the court before the November 2 deadline. While the law firm Glancy Prongay Wolke & Rotter is currently organizing the class, individuals retain the right to select their own counsel or remain absent class members. No class has been certified at this stage of the proceedings, and previous firm successes in similar securities litigation do not guarantee recovery for this specific case.